Treatment with rituximab — approved for certain cancers to reduce the levels of antibody-producing immune cells — is effective to control swelling attacks in people with acquired angioedema, particularly in cases where the disease is linked to an underlying lymphoma, or a blood cancer that develops in the lymphatic…
Even with long-term preventive treatment, many people with hereditary angioedema still sometimes have swelling attacks that require on-demand treatment, a review study finds.
Children with hereditary angioedema (HAE) may have dozens of swelling attacks until they receive a correct diagnosis of the disease, according to a study in a hospital in Turkey, where the median delay was three years. “Awareness of the symptoms of HAE is necessary and correct diagnosis is…
A 3-point score increase is the minimum change on the widely used Angioedema Control Test (AECT) to reflect meaningful improvement in disease control for people with recurrent angioedema, a study showed. The AECT was developed to help patients keep score of disease control over a recall period, but…
The European Medicines Agency (EMA) has granted priority medicines (PRIME) designation to Intellia Therapeutics’ NTLA-2002, an experimental gene-editing therapy to prevent swelling attacks in people with hereditary angioedema (HAE). A PRIME designation supports the development of experimental therapies that address unmet medical needs. Eligibility for this status is…
The design of an ongoing Phase 3 clinical trial testing sebetralstat as an on-demand oral treatment for swelling attacks in hereditary angioedema (HAE) was based on feedback from patients and data from a previous Phase 2 trial. The approach was described in the study “Evaluation…
On-demand and preventive treatment with either icatibant injection or C1 inhibitor (C1-INH) concentrates — which are approved for hereditary angioedema (HAE) — also can help people with acquired angioedema keep swelling under control, according to a small study in Germany. People severely affected with acquired angioedema and no “underlying condition…
Up to one year of treatment with Takhzyro (lanadelumab) significantly reduced rates of swelling attacks and improved quality of life for children with hereditary angioedema (HAE) ages 2 through 11, according to results from the Phase 3 SPRING clinical trial. Results from the trial helped support the U.S.
New treatments for hereditary angioedema (HAE) have been life-changing for people in the U.K., but more and better efforts are needed to educate emergency workers on providing care, according to a new study. The survey study found that HAE patients in Great Britain still frequently have upsetting experiences when…
The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended the approval of Takhzyro (lanadelumab) for the routine prevention of hereditary angioedema (HAE) attacks in children starting at age 2. Based on a positive opinion from the CHMP, the European…
Get regular updates to your inbox.
